Login to Your Account

BioMarin, Genzyme Gain Panel Support For Aldurazyme BLA

By Kim Coghill

Thursday, January 16, 2003
An FDA panel supported data submitted by Genzyme General and partner BioMarin Pharmaceutical Inc. for Aldurazyme, an enzyme replacement therapy for the treatment of a rare degenerative disease, mucopolysaccharidosis-1 (MPS-1). (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription